VitalCare Signs LOI For Diabetes Treatment Center In Utah: Center Will Provide iCAT Therapy for Type 1 and Type 2 Diabetics

VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI) a Nevada corporation, today announced they have signed a letter of intent to establish a joint-venture relationship with South Valley Inpulse Center, LLC, an existing Diabetes Treatment Center in Draper, Utah. The center will be administering the FDA approved iCAT treatment for Type 1 and Type 2 diabetes patients.

CARSON CITY, Nev. (Business Wire EON) April 28, 2008 -- VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI) a Nevada corporation, today announced they have signed a letter of intent to establish a joint-venture relationship with South Valley Inpulse Center, LLC, an existing Diabetes Treatment Center in Draper, Utah. The center will be administering the FDA approved iCAT treatment for Type 1 and Type 2 diabetes patients.

This is the part of our Mid-West launch and we are excited to be offering iCAT therapy to diabetics in this region. We see this as an opportunity to work with an established team of healthcare professionals.

Jimmy McDougald, CEO, stated, “This is the part of our Mid-West launch and we are excited to be offering iCAT therapy to diabetics in this region. We see this as an opportunity to work with an established team of healthcare professionals.”

Diana Harrison, Managing Partner of South Valley Inpulse Center, said, “We are excited about this opportunity to work with VitalCare to expand our program, giving more people access to this treatment and the hope in a better quality of life.”

About VitalCare Diabetes Treatment Centers, Inc.

VitalCare Diabetes Treatment Centers, Inc. is a company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector, with an emphasis in bringing “Cutting Edge” medical devices and healthcare services direct to consumers, focusing on an emerging FDA approved, US and European Patented technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as “Intracellular Activation Therapy (iCAT)”.

Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Inc.’s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward- looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Inc.’s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare’s filings with the Securities and Exchange Commission.